Fig. 4: Pseudovirus serum neutralisation over time.

A ConM-pseudovirus serum neutralisation at each vaccination baseline (zero, eight and 24 weeks), two weeks post-vaccination (two, 10 and 26 weeks) and at 48 and 72 weeks. Values are the serum dilution at which relative luminescence units (RLUs) were reduced 50% (ID₅₀) or 80% (ID₈₀) compared to virus control wells. Values and error bars indicate the median ID₅₀ or ID₈₀ and interquartile range (IQR). B ConM-pseudovirus serum neutralisation ID₅₀ values per vaccine group over time. Values and error bars indicate the median ID₅₀ and IQR. Full dose group N = 13. Fractional (Fx) dose group N = 10. Week 10 p = 0.33. C ConM-pseudovirus serum neutralisation ID₅₀ values per sex at birth over time. Values and error bars indicate the median ID₅₀ and IQR. Female N = 13. Male N = 10. Week 10 p = 0.0006; week 26 p = 0.0011; week 48 p = 0.016; week 72 p = 0.0077. D ConM-pseudovirus serum neutralisation ID₅₀ values per sex at birth at 10, 26, 48 and 72 weeks. Values and error bars indicate the median ID₅₀ and IQR. Respective fold changes are shown. Transgender individual indicated in grey. E Week 26 sera were tested against a panel representative of global HIV-1 varieties, as indicated. All figures represent the per-protocol cohort (N = 23). Green arrows signify difference in vaccine dose at 24 weeks. Differences between groups and sex were calculated by a two-tailed Mann–Whitney U-test. *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant. Source data are provided as a Source Data file.